Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
Strange, as the r&d relief in UK for SME (500 employees or less, up to 100m euro turnover) is extremely generous at 230%. Id be abusing that to the hilt if it was my company, would never pay corporation tax again!
MrA - Lots of companies have developed/are developing tests, vast majority are either too expensive, not appropriate, too inaccurate, cannot be upscaled and dont have the UK wide collaborations in place. And more importantly, none have affimers. Maybe they'd like to licence some?
Similar issue car manufacturers are having with electric cars - none have access to the tesla charging network (affimers), all are trying to go it alone using sh*tty infrastructure. Anyone can shove a battery and motor in a car and call it done. Tesla might not be the cheapest, but they're doing ok and their name is synonymous with electric cars, just like ours will be 6 months from now with Lateral flow tests.
Been a good day - blue across the board in my investment so far, can't remember the last time that happened, although UFO will probably scupper that.
Do I pay myself and wife another dividend at 32.5% tax rate to invest, or wait till 6th April and hope it hasn't risen more than 32.5% in the meantime? I know I could take a further dir loan but then I'll pay tax as at £10k already, and dont like the idea of borrowing to invest...
Wondered why we were up past the dizzy heights of 7 40, and now I know why. Nova need to RNS this, not just stick it in a twitter post for 10 followers. This is the type of PR they need massive help with, looks like things still haven't improved.
I know you're massively under water porky hence the incessant ramping, but whats with the obsession with Avacta? They're at the beginning of their journey which could see a multi billion mcap in next few years, take your frustration out on the MMs
Odx fell because holders are hoping for a multi million pound contract, and Colin basically said that's not realistic, ignore the £300m figure, they're going to make pennies, not pounds from each test. Another DHSC contract even if no where near the scale of phase 2 will get this back above £10 imo.
I'd rather see a 3 year £100m pa deal than a one off £350m.
https://mobile.twitter.com/HarpurUk/status/1371203667127324677
Interesting...
When we had our part 2 of of ISO 27001 audit from BSI which took place several months after part 1, once audit was complete they don't award certification there and then, but take the evidence and 'recommend' that you're awarded certification. If there are any minor non conformities the process to remedy them can be logged and identifed to the auditors even when audit completed and will not constitute a fail (only a major non conformity will mean a fail and having to rebook an audit) - I imagine all iso standards will be similar. This typically arrives 2 weeks later (pre covid days). If their audit is end march, will probably be April when officially accredited.
"It has helped people confirm that the illness they experienced was indeed COVID-19. It also has limitations as some people do not develop IgG antibodies after having COVID-19."
That is true, but what would be the point other than to say you've had covid at some point in the last 12 months. You can still catch it again and be contagious, even with antibodies present, doesn't (or shouldn't) be a deciding factor on whether to get vaccinated, nor should it be used to decide whether to get a yearly booster or not. Antibodies waning? Get your yearly booster. Antibodies ok but likely to fade in next 6 months? Get your yearly booster. Antibody tests are great for chronic illnesses like HIV, not so much for things like covid, all imo.
I think the market will give zero ****s about antibody tests just like the dhsc, esp as it's cheaper just to give another jab. The world is waiting for a decent AN or sakiva lft antigen test, not antibody.
Fireblade, so you want the company to disclose that none disclosure agreements are in place? Brilliant. Company is a sitting duck at these prices, could well touch £5 range before end of the month, in which case I might have a whipround and start a buyout.
Braveheart eh? Can just picture Wembley now, 80000 fans queuing up to blow in a machine and waiting 3 minutes. Would take 166 days to test everyone. If you start now you might just make it in time for the charity shield.
£5 imo is the realistic minimum between now and end of year taking in to account UK govt orders alone. I'm hoping the US presents itself as a far bigger market in the summer. If Ava trials are a success, it gives us the long term potential that the likes of Novacyt are currently missing. So, possible £1bn+ revenue for next few years, typical p/e of 15...
I would like to think Al has negotiated at least a partial fixed amount to licence affimers to the consortium, eg £250m a year for 2 years and then an additional amount on top per each test sold, and if contract is ended early by govt, the stock piled tests remain our property and can be sold abroad at higher mark ups.
Basically if someone wants to buy Avacta for under a tenner a share, they have less than 30 days to do so. Otherwise we'll be in a position that only the likes of Amazon can afford us.
Before covid was a thing, 1 in 12 international passengers on a flight were British - more than any other country in the world. Pent up demand will mean numbers will still be pretty damn high this year. That's 126 million. That's a lot of potential overpriced private PCR test revenue and testing machines, before you even consider govt contracts and sales to other countries. None of these sales individually are probably worth an RNS, but in total that could be £50m+ revenue alone. World will take years to be fully vaccinated and even then boosters will be needed and testing especially between countries for the next 3-5 years imo.
https://www.google.com/amp/s/www.independent.co.uk/travel/news-and-advice/british-travellers-iata-world-air-transport-statistics-a9029366.html%3famp
The British consortium might be getting all the headlines over the next month or so, but as above, revenues for this year I reckon will be on a par with last year, and quite possibly the year after. We could have £300m cash in the bank by end of 2022. Sooner or later the market will apply an appropriate p/e. The fact nova are very coy about sales isn't because there aren't any, but I'm now coming round to the conclusion the SP is being kept down deliberately, news surpressed and little in the way of acquisitions outside of manufacturers directly related to our cause, rather tha diversification, for one particular reason...